Gapping up
In reaction to strong earnings/guidance: GME +10.8%, CERE +7.1%, HIMX +6.4%, ACST +5.8%, ZLTQ +5.7%, DRWI +4.9%, LLTC +4.3%, FLDM +2.1%, NEPT +1%, PRXI +0.8%, LAND +0.5%
Other news: ZIOP +50.9% (co and partner Intrexon (XON) announced licensing agreement with The University of Texas MD Anderson Cancer Center), XON +11.1% (ZIOP and partner XON announced licensing agreement with The University of Texas MD Anderson Cancer Center), FCE.A +6.3% (co's Board of Directors has approved a plan for the company to pursue conversion to REIT status), OCN +6% (co announced it is fully cooperating with the California Department of Business Oversight (DBO) to resolve an administrative action dated October 3, 2014), BCRX +5.3% (receives positive opinion on European orphan drug designation for BCX4161), DEJ +5.1% (announced Dejour B-100 Woodrush oil well swab tests at 400 BOPD), NOK +2.8% (MSFT announced release of 2 new Lumina phones), GPRO +2.2% (rebounding after yday's weakness), FLEX +1.2% (favorable commentary on Tuesday's Mad Money), TASR +1.1% (announces multiple large orders of it's AXON body-worn video cameras and EVIDENCE.com solution), NEPT +1% (co and its subsidiary NeuroBioPharm announced agreement which will result in the indirect acquisition by Neptune of all the issued and outstanding shares of NeuroBio; co also reported earnings), AZN +0.8% (announces PEGASUS-TIMI 54 study of BRILINTA met primary endpoint in both 60mg and 90mg doses)
Analyst comments: BEBE +4% (upgraded to Buy at Janney), ARMH +2% (upgraded to Mkt Perform from Underperform at Bernstein), NFLX +1.6% (upgraded to Buy from Hold at Stifel), PSO +1.4% (upgraded to Neutral from Sell at Goldman), DTSI +1% (upgraded to at ), BLK +0.9% (upgraded to Buy from Neutral at Goldman), PHG +0.8% (upgraded to Neutral from Underperform at Exane BNP Paribas), WETF +0.8% (upgraded to Buy from Neutral at Goldman), FB +0.7% (target raised to $102 from $88 at Credit Suisse), MXIM +0.5% (upgraded to Overweight from Neutral at JP Morgan)
In reaction to strong earnings/guidance: GME +10.8%, CERE +7.1%, HIMX +6.4%, ACST +5.8%, ZLTQ +5.7%, DRWI +4.9%, LLTC +4.3%, FLDM +2.1%, NEPT +1%, PRXI +0.8%, LAND +0.5%
Other news: ZIOP +50.9% (co and partner Intrexon (XON) announced licensing agreement with The University of Texas MD Anderson Cancer Center), XON +11.1% (ZIOP and partner XON announced licensing agreement with The University of Texas MD Anderson Cancer Center), FCE.A +6.3% (co's Board of Directors has approved a plan for the company to pursue conversion to REIT status), OCN +6% (co announced it is fully cooperating with the California Department of Business Oversight (DBO) to resolve an administrative action dated October 3, 2014), BCRX +5.3% (receives positive opinion on European orphan drug designation for BCX4161), DEJ +5.1% (announced Dejour B-100 Woodrush oil well swab tests at 400 BOPD), NOK +2.8% (MSFT announced release of 2 new Lumina phones), GPRO +2.2% (rebounding after yday's weakness), FLEX +1.2% (favorable commentary on Tuesday's Mad Money), TASR +1.1% (announces multiple large orders of it's AXON body-worn video cameras and EVIDENCE.com solution), NEPT +1% (co and its subsidiary NeuroBioPharm announced agreement which will result in the indirect acquisition by Neptune of all the issued and outstanding shares of NeuroBio; co also reported earnings), AZN +0.8% (announces PEGASUS-TIMI 54 study of BRILINTA met primary endpoint in both 60mg and 90mg doses)
Analyst comments: BEBE +4% (upgraded to Buy at Janney), ARMH +2% (upgraded to Mkt Perform from Underperform at Bernstein), NFLX +1.6% (upgraded to Buy from Hold at Stifel), PSO +1.4% (upgraded to Neutral from Sell at Goldman), DTSI +1% (upgraded to at ), BLK +0.9% (upgraded to Buy from Neutral at Goldman), PHG +0.8% (upgraded to Neutral from Underperform at Exane BNP Paribas), WETF +0.8% (upgraded to Buy from Neutral at Goldman), FB +0.7% (target raised to $102 from $88 at Credit Suisse), MXIM +0.5% (upgraded to Overweight from Neutral at JP Morgan)